Loading...

Pharmaceutical Expansion Will Unlock Global Healthcare Opportunities Despite Risks

Published
23 Feb 25
Updated
20 Sep 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-4.0%
7D
2.7%

Author's Valuation

JP¥9.4k10.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 20 Sep 25

Fair value Increased 1.27%

Otsuka Holdings’ consensus valuation remains stable as a modest decline in revenue growth forecasts to 2.3% is offset by a slight improvement in net profit margin to 12.31%, resulting in a marginal increase in the Analyst Price Target from ¥9282 to ¥9400. What's in the News Increased interim and year-end dividends to JPY 70 per share each, up from JPY 60 per share previously.

Shared on 05 Sep 25

As there were no notable changes in Otsuka Holdings' consensus revenue growth (2.4% per annum) or net profit margin (11.89%), the analyst price target remained unchanged at ¥9,282. What's in the News Raised full-year dividend guidance to JPY 140 per share, up from JPY 120 previously, reflecting ongoing commitment to shareholder returns under the fourth midterm plan.

Shared on 01 May 25

Fair value Increased 0.55%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 3.01%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 1.31%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.18%

AnalystConsensusTarget has increased revenue growth from 2.3% to 2.8%.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 2.30%

AnalystConsensusTarget has increased revenue growth from 2.1% to 2.3%.

Shared on 12 Mar 25

Fair value Increased 0.28%